264 related articles for article (PubMed ID: 27476133)
1. Testosterone and the Prostate: Artifacts and Truths.
DeLay KJ; Kohler TS
Urol Clin North Am; 2016 Aug; 43(3):405-12. PubMed ID: 27476133
[TBL] [Abstract][Full Text] [Related]
2. Testosterone Replacement Therapy and BPH/LUTS. What is the Evidence?
Baas W; Köhler TS
Curr Urol Rep; 2016 Jun; 17(6):46. PubMed ID: 27068735
[TBL] [Abstract][Full Text] [Related]
3. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.
Oudot A; Oger S; Behr-Roussel D; Caisey S; Bernabé J; Alexandre L; Giuliano F
BJU Int; 2012 Nov; 110(9):1352-8. PubMed ID: 22448674
[TBL] [Abstract][Full Text] [Related]
4. Testosterone supplementation does not worsen lower urinary tract symptoms.
Pearl JA; Berhanu D; François N; Masson P; Zargaroff S; Cashy J; McVary KT
J Urol; 2013 Nov; 190(5):1828-33. PubMed ID: 23764078
[TBL] [Abstract][Full Text] [Related]
5. Improved Lower Urinary Tract Symptoms Associated With Testosterone Replacement Therapy in Japanese Men With Late-Onset Hypogonadism.
Okada K; Miyake H; Ishida T; Sumii K; Enatsu N; Chiba K; Matsushita K; Fujisawa M
Am J Mens Health; 2018 Sep; 12(5):1403-1408. PubMed ID: 27256990
[TBL] [Abstract][Full Text] [Related]
6. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
[TBL] [Abstract][Full Text] [Related]
7. Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia.
De Nunzio C; Salonia A; Gacci M; Ficarra V
World J Urol; 2020 Nov; 38(11):2771-2779. PubMed ID: 32060633
[TBL] [Abstract][Full Text] [Related]
8. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
[TBL] [Abstract][Full Text] [Related]
9. Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia.
Lepor H
Urol Clin North Am; 2016 Aug; 43(3):311-23. PubMed ID: 27476124
[TBL] [Abstract][Full Text] [Related]
10. PDE-5 Inhibitors for BPH-Associated LUTS.
Brousil P; Shabbir M; Zacharakis E; Sahai A
Curr Drug Targets; 2015; 16(11):1180-6. PubMed ID: 26470799
[TBL] [Abstract][Full Text] [Related]
11. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
Silva J; Silva CM; Cruz F
Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
[TBL] [Abstract][Full Text] [Related]
12. Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis.
Kohn TP; Mata DA; Ramasamy R; Lipshultz LI
Eur Urol; 2016 Jun; 69(6):1083-90. PubMed ID: 26874809
[TBL] [Abstract][Full Text] [Related]
13. Late-onset hypogonadism: Prostate safety.
Miranda EP; Torres LO
Andrology; 2020 Nov; 8(6):1606-1613. PubMed ID: 32056383
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
[TBL] [Abstract][Full Text] [Related]
15. Tadalafil - a therapeutic option in the management of BPH-LUTS.
Carson CC; Rosenberg M; Kissel J; Wong DG
Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
[TBL] [Abstract][Full Text] [Related]
16. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
[TBL] [Abstract][Full Text] [Related]
17. Testosterone does not affect lower urinary tract symptoms while improving markers of prostatitis in men with benign prostatic hyperplasia: a randomized clinical trial.
Rastrelli G; Cipriani S; Lotti F; Cellai I; Comeglio P; Filippi S; Boddi V; Della Camera PA; Santi R; Boni L; Nesi G; Serni S; Gacci M; Maggi M; Vignozzi L
J Endocrinol Invest; 2022 Jul; 45(7):1413-1425. PubMed ID: 35298833
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
[TBL] [Abstract][Full Text] [Related]
19. Do we really need herbal medicine in LUTS/BPH treatment in the 21
Pinggera GM; Frauscher F
Expert Opin Drug Saf; 2016 Dec; 15(12):1573-1575. PubMed ID: 27461908
[No Abstract] [Full Text] [Related]
20. Testosterone and benign prostatic hyperplasia.
Jarvis TR; Chughtai B; Kaplan SA
Asian J Androl; 2015; 17(2):212-6. PubMed ID: 25337845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
